Anterior ischemic optic neuropathy caused by interferon alpha therapy

Gupta, Rajiv; Singh, Sumit; Tang, Rosa A.; Blackwell, Thomas A.; Schiffman, Jade S.

doi:10.1016/s0002-9343(02)01102-6

Cited by 52 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interferon-alpha is a glycoprotein with antiviral, antitumour, and antiangiogenic effects used as adjuvant therapy for malignancies, including melanoma, leukaemia, and lymphoma, and for chronic hepatitis C. Several reports [58][59][60] have confirmed the development of NAION, usually bilateral, sequential, and temporally associated with the institution of interferon therapy; recurrences with restarting the medication also have been described. The clinical course is variable, with some patients showing improvement with discontinuation of therapy.…”

Section: Risk Factorsmentioning

confidence: 99%

Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy

Miller

Arnold

2014

Eye

172

132

View full text Add to dashboard Cite

Nonarteritic anterior ischaemic optic neuropathy (NAION) is the most common acute optic neuropathy in patients over the age of 50 and is the second most common cause of permanent optic nerve-related visual loss in adults after glaucoma. Patients typically present with acute, painless, unilateral loss of vision associated with a variable visual field defect, a relative afferent pupillary defect, a swollen, hyperaemic optic disc, and one or more flame-shaped peripapillary retinal haemorrhages. The pathogenesis of this condition is unknown, but it occurs primarily in patients with structurally small optic discs that have little or no cup and a variety of underlying vascular disorders that may or may not be known at the time of visual loss. There is no consistently beneficial medical or surgical treatment for the condition, but there are now animal models that allow testing of various potential therapies. About 40% of patients experience spontaneous improvement in visual acuity. Patients in whom NAION occurs in one eye have a 15-19% risk of developing a similar event in the opposite eye over the subsequent 5 years.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy

Miller

Arnold

2014

Eye

172

132

View full text Add to dashboard Cite

show abstract

“…27 Interferon-alpha may cause NAION through the deposition of immune complexes in the optic disc circulation resulting in the development of a bilateral, sequential NAION in some patients. 28,29 4.6. Cataract surgery Patients who develop NAION following cataract extraction in one eye are at a significantly greater risk of developing NAION in the fellow eye if cataract extraction is subsequently performed in that eye.…”

Section: Medicationsmentioning

confidence: 99%

Non-arteritic anterior ischaemic optic neuropathy: A review and update

Kerr

Chew

Danesh‐Meyer

2009

Journal of Clinical Neuroscience

120

View full text Add to dashboard Cite

“…Vascular changes can be observed during IFN-a2a treatment and the ocular vascular complications that have been reported during this treatment are evidence of such changes. These complications can vary from the common benign vasculopathy to severe central retinal artery occlusion or ischemic anterior optic disc neuritis [26][27][28][29]. These modifications of circulating conditions in capillaries and large vessels can participate in the occurrence of VKH-like disease in these patients.…”

Section: Discussionmentioning

confidence: 99%

Interferon-α2a and Vogt–Koyanagi–Harada disease: a double-edged sword?

et al. 2007

View full text Add to dashboard Cite

Successful therapy based on the use of interferon-alpha has been reported in different types of severe chronic uveitis. The immunomodulatory effects of this drug, combined with its antiviral properties seem to contribute to its efficacy in the treatment of different forms of severe and refractory uveitis such as Vogt-Koyanagi-Harada disease, Behçet-associated uveitis, or even human herpes virus 8 (HHV-8) associated uveitis. At the same time, severe ocular complications have been reported in patients treated with interferon-alpha for chronic viral hepatitis C. Among these complications, six cases of Vogt-Koyanagi-Harada-like disease have been described.We report a small case series of two patients with refractory Vogt-Koyanagi-Harada disease, treated with interferon-alpha and discuss the potential benefits or detrimental role of interferon therapy in these patients.

show abstract

Anterior ischemic optic neuropathy caused by interferon alpha therapy

Cited by 52 publications

References 8 publications

Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy

Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy

Non-arteritic anterior ischaemic optic neuropathy: A review and update

Interferon-α2a and Vogt–Koyanagi–Harada disease: a double-edged sword?

Contact Info

Product

Resources

About